Establishment of laboratory medicine of heparin-induced thrombocytopenia
Project/Area Number |
16H02637
|
Research Category |
Grant-in-Aid for Scientific Research (A)
|
Allocation Type | Single-year Grants |
Section | 一般 |
Research Field |
Laboratory medicine
|
Research Institution | The University of Tokyo |
Principal Investigator |
Yatomi Yutaka 東京大学, 医学部附属病院, 教授 (60200523)
|
Research Collaborator |
YASUMOTO ATSUSHI
|
Project Period (FY) |
2016-04-01 – 2019-03-31
|
Project Status |
Completed (Fiscal Year 2018)
|
Budget Amount *help |
¥24,310,000 (Direct Cost: ¥18,700,000、Indirect Cost: ¥5,610,000)
Fiscal Year 2018: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
Fiscal Year 2017: ¥7,800,000 (Direct Cost: ¥6,000,000、Indirect Cost: ¥1,800,000)
Fiscal Year 2016: ¥8,840,000 (Direct Cost: ¥6,800,000、Indirect Cost: ¥2,040,000)
|
Keywords | ヘパリン起因性血小板減少症 / HIT抗体検査 / 機能的HIT抗体検査 / サイトカラシンB / 臨床検査医学 / 臨床 / 内科 / シグナル伝達 |
Outline of Final Research Achievements |
Anti-platelet factor 4 (PF4)/heparin antibodies-induced platelet activation is important for thrombosis in heparin-induced thrombocytopenia (HIT), and we established in vitro functional HIT assay system using mouse anti-PF4/heparin monoclonal antibody (HIT-MoAb). We have found that platelet activation via the clustering of FcγRIIa involves cytochalasin-sensitive cytoskeletal reorganization and that cytochalasin B (CB) significantly enhanced HIT-MoAb-induced platelet activation, accompanied by platelet aggregation. From a practical viewpoint, CB may be useful for improving the sensitivity of HIT functional assays. We have also developed a facile immunological HIT assay system, which can be applied to IVD in the future.
|
Academic Significance and Societal Importance of the Research Achievements |
ヘパリン起因性血小板減少症(heparin-induced thrombocytopenia; HIT)は,抗血栓薬(抗凝固薬)として広く臨床において使用されているヘパリンの重大な副作用であるが,早期かつ的確な診断が難しいことが多く,その診断手法の向上が望まれている.我々は,本診断における二本柱である免疫学的HIT抗体,機能的HIT抗体の手法の向上につながる成果をあげることができた.
|
Report
(4 results)
Research Products
(9 results)